Advertisement
Organisation › Details
Follicum AB
Follicum is a biotech company focusing on the discovery and development of peptide-based drugs. The primary focus is in hair growth stimulation, where Follicum has obtained very promising results with FOL-005 in a recently completed clinical trial. In diabetes, Follicums research has resulted in a new peptide class which significantly increases the release of insulin in pre-clinical models. The company was founded in 2011, and is based in Lund, Sweden. Follicum is listed on the Swedish small cap exchange Spotlight since 2014. *
Start | 2011-01-01 established | |
Industry | peptide-based drug | |
Person | Alenfall, Jan (Follicum 201902 CEO) | |
Person 2 | Gårdemyr, Gunnar (Follicum 201902 before Targovax/Polaris + Nycomed/Takeda) | |
Region | Lund | |
Country | Sweden | |
Street | 22 Scheelevägen | |
City | 22363 Lund | |
Tel | +46-46-192197 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Follicum AB. (2/11/19). "Press Release: Follicum Selects Novel Peptide Drug Candidate for the Treatment of Diabetes and Protection of Beta Cells". | ||
Record changed: 2024-02-12 |
Advertisement
More documents for Follicum AB
- [1] Follicum AB. (2/11/19). "Press Release: Follicum Selects Novel Peptide Drug Candidate for the Treatment of Diabetes and Protection of Beta Cells"....
- [2] Follicum AB. (2/4/19). "Press Release: Follicum’s New Topical Formulation of FOL-005 Results in Increased Hair Growth on a Par with Leading Commercial Product"....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top